EpiEndo Pharmaceuticals expands its leadership team, appointing Stefan Petursson as CFO
REYKJAVIK, ICELAND – 24 March 2022 – EpiEndo Pharmaceuticals is pleased to announce the appointment of Stefan Petursson as Chief Financial Officer (CFO), starting 1. April, 2022. EpiEndo Pharmaceuticals is a privately held biopharmaceutical company developing a therapeutic pipeline for the treatment of inflammatory disorders involving the epithelium, addressing underlying causal pathways of disease. Mr. Petursson is taking over the role of CFO from Finnur Einarsson who will now focus on his role as Chief Operations Officer (COO).
“I am delighted to welcome Stefan to EpiEndo as CFO," commented Maria Bech, CEO of EpiEndo Pharmaceuticals. Stefan brings vast experience and knowledge from the financial and banking world to the team, which will be invaluable for us as we continue to grow and develop the Company. I would also like to thank Finnur for his important contribution to the Company’s development in his combined CFO/COO role. I look forward to continuing to work with him as COO,”.
Stefan Petursson added: “It is very exciting to be joining the EpiEndo team. The Company is doing ground-breaking biopharmaceutical
work that has the potential to improve the well-being of millions of patiens. EpiEndo has already made substantial progress and I hope to be able to assist the Company in reaching critical milestones going forward”.
Mr. Stefan Petursson has a Cand. Oecon degree from the University of Iceland and an MBA from Babson College in Boston. During his 20+ years’ as a CFO at Landsvirkjun and Arion Banks, he helped the companies grow and develop, and while at Arion Bank, successfully completed an IPO in both Sweden and Iceland. In addition to his work as CFO at EpiEndo, Mr. Petursson will continue to serve on the Board of Directors at several entities.